Evidence map›Paper›PMID 34988333›Full record

ArticleJournal of clinical and translational research2021

Subacute neurological deficits and respiratory insufficiency due to intrathecal methotrexate.

Sjoerd I P J de Faber, Pim G N J Mutsaers, Martin J van den Bent, Matthijs van der Meulen

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in Journal of clinical and translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Primary central nervous system lymphoma.Journal of neurology · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sjoerd I P J de FaberDepartment of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Pim G N J MutsaersDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Martin J van den BentDepartment of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Matthijs van der MeulenDepartment of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Erasmus MC Cancer Institute · NLHaga Hospital · NLMedisch Spectrum Twente · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimWe present a case of a 22-year-old male diagnosed with B-cell acute lymphoblastic leukemia who received intrathecal (IT) methotrexate (MTX) in addition to his systemic chemotherapy regime. During induction treatment, he presented with a rapidly progressive bilateral paresis, anarthria, and respiratory insufficiency requiring intubation. The brain magnetic resonance imaging showed bilateral lesions with diffusion restriction of the corona radiata/centrum semi-ovale without other abnormalities. He recovered spontaneously without neurological sequelae. The clinical course combined with the radiological findings is suspect for an IT-MTX-induced leukoencephalopathy. RELEVANCE FOR PATIENTS: Although neurological deficits after IT-MTX are rare and in most cases self-limiting, it should be recognized as a cause for rapid neurological decline after excluding other causes.

Indexed as

acute lymphoblastic leukemialeukoencephalopathymethotrexateneurotoxicity

Identifiers

PMID34988333
PMCPMC8717579
OpenAlexW4206854803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.